About 29 results found for searched term "PAK" (0.147 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2581 | Ampalex | GluR |
| Ampakine CX516, BDP 12 | ||
| Ampalex is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator which can be used for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI). | ||
| M7068 | NVS PAK1 1 | Others |
| NVS PAK1 1 is a potent and selective PAK1 inhibitor. | ||
| M9528 | KPT-9274 | PAK |
| PAK4-IN-1 | ||
| KPT-9274, also known as PAK4-IN-1, is a potent, selective and dual PAK4/NAMPT inhibitor with IC50s of less than 100 and 120 nM, respectively. | ||
| M29439 | NVS-PAK1-C | PAK |
| NVS-PAK1-C is a potent, ATP-competitive and specific allosteric PAK1 inhibitor probe with IC50 values of 5 nM and 6 nM for dephosphorylated PAK1 and phosphorylated PAK1, respectively. NVS-PAK1-C is also against dephosphorylated PAK2 (IC50=270 nM) and phosphorylated PAK2 (IC50=720 nM). | ||
| M3110 | PF-3758309 | PAK |
| PF-03758309 | ||
| PF-3758309 is a potent (Kd = 2.7 nM), ATP-competitive PAK4 inhibitor with IC50 / Ki values of 1.3 / 18.7 nM. | ||
| M4382 | Artemisinine | Akt |
| Qinghaosu; NSC 369397 | ||
| Artemisinin (Qinghaosu) is a kind of sesquiterpene lactone, an antimalarial drug isolated from the aboveground part of Artemisia annua L. Artemisinin inhibits AKT signaling by decreasing pAKT in a dose-dependent manner. Artemisinin can reduce the proliferation, migration, invasion, tumorigenesis and metastasis of cancer cells, and Artemisinin has neuroprotective effects. | ||
| M5322 | FRAX486 | PAK |
| FRAX486 is a potent p21-activated kinase (PAK) inhibitor with IC50 values of 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively. | ||
| M5323 | FRAX597 | PAK |
| FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively. | ||
| M5371 | 5-Aminosalicylic acid | NF-κB |
| Mesalamine; 5-ASA; Mesalazine | ||
| 5-aminosalicylic acid (Mesalamine) is a specific PPARγ agonist that also inhibits P21-activated kinase 1 (PAK1) and NF-κB. | ||
| M8885 | Rafoxanide | Anti-infection |
| Rafoxanide is a novel allosteric inhibitor of SPAK and OSR1. | ||
| M13705 | FRAX1036 | PAK |
| FRAX1036 is a PAK inhibitor with Kis of 23.3 nM, 72.4 nM, and 2.4 μM for PAK1, PAK2 and PAK4, respectively. | ||
| M13706 | G-5555 | PAK |
| G-5555 is a potent p21-activated kinase 1 (PAK1) inhibitor with Kis of 3.7 nM and 11 nM for PAK1 and PAK2, respectively. | ||
| M13707 | G-5555 hydrochloride | PAK |
| G-5555 hydrochloride is a potent and selective p21-activated kinase 1 (PAK1) inhibitor with a Ki of 3.7 nM. | ||
| M14000 | Fingolimod | S1P Receptor |
| FTY720 free base | ||
| Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant. | ||
| M14176 | MAPK13-IN-1 | p38 MAPK |
| MPAK13-IN-1 is a MAPK13 (p38δ) inhibitor, with an IC50 of 620 nM. | ||
| M20999 | Y-27632 | ROCK |
| Y-27632 is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK. | ||
| M21035 | LCH-7749944 | PAK |
| GNF-PF-2356 | ||
| LCH-7749944 (GNF-PF-2356) is a novel and potent p21-activated kinase 4 (PAK4) inhibitor with an IC50 of 14.93 μM and has less potently inhibitory effect against PAK1, PAK5 and PAK6. LCH-7749944 causes successful inhibition of EGFR activity due to its inhibitory effect on PAK4. | ||
| M27987 | CC214-2 | mTOR |
| CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin-resistant signaling and the growth of glioblastomas in vitro and in vivo. | ||
| M28109 | PF-3758309 hydrochloride | PAK |
| PF-03758309 hydrochloride | ||
| PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation. | ||
| M28319 | GNE 2861 | PAK |
| GNE 2861 is a PAK inhibitor that displays group II selectivity. GNE 2861 inhibits PAK4, PAK5 and PAK6 with IC50s of 7.5, 36, 126 nM, respectively. | ||
| M29025 | G-9791 | PAK |
| G-9791, a poyridone side chain analogue, is a potent PAK inhibitor with Ki values of 0.95 nM and 2.0 nM for PAK1 and PAK2, respectively. | ||
| M29109 | AZ13705339 | PAK |
| AZ13705339 is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 can be used in the research of cancers. | ||
| M31006 | AZ13705339 hemihydrate | PAK |
| AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers. | ||
| M31007 | PF-3758309 dihydrochloride | PAK |
| PF-03758309 dihydrochloride | ||
| PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation. | ||
| M41570 | ZMF-23 | PAK |
| ZMF-23 is a PAK1/HDAC6 dual inhibitor. | ||
| M43397 | Leniolisib phosphate | PI3K |
| Leniolisib (CDZ173) phosphate is a first-in-class, potent and selective PI3Kδ inhibitor with an IC50 value of 11 nM.Leniolisib is more selective for PI3K-δ than PI3K-α (28-fold), PI3K-β (43-fold) and PI3K-γ (257-fold). -γ (257-fold). In a cellular assay, Leniolisib decreased pAKT pathway activity and inhibited the proliferation and activation of B and T cell subsets. | ||
| M49642 | AZA197 | PAK |
| AZA197 is a selective small molecule inhibitor of Cdc42.AZA197 suppresses colon cancer cell proliferation, cell migration, invasion and increases apoptosis by down-regulating the PAK1 and ERK signaling pathways in vitro. | ||
| M57078 | PI3Kα-IN-22 | PI3K |
| PI3Kα-IN-22 is an orally active, potent and selective inhibitor of PI3KαH1047R, with an IC50 of 1 nM for pAKT T47D AlphaLISA. | ||
| M57055 | ZT-1a | Others |
| ZT-1a is a potent, non-ATP-competitive and selective SPAK inhibitor. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
